Marker Cost Of Revenue vs Ebitda Analysis

MRKR Stock

USD 4.72 0.83 21.34%

Marker Therapeutics financial indicator trend analysis is infinitely more than just investigating Marker Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Marker Therapeutics is a good investment. Please check the relationship between Marker Therapeutics Cost Of Revenue and its Ebitda accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.

Cost Of Revenue vs Ebitda

Cost Of Revenue vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Marker Therapeutics Cost Of Revenue account and Ebitda. At this time, the significance of the direction appears to have pay attention.

The correlation between Marker Therapeutics' Cost Of Revenue and Ebitda is -0.94. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Ebitda in the same time period over historical financial statements of Marker Therapeutics, assuming nothing else is changed. The correlation between historical values of Marker Therapeutics' Cost Of Revenue and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Marker Therapeutics are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Cost Of Revenue i.e., Marker Therapeutics' Cost Of Revenue and Ebitda go up and down completely randomly.

Correlation Coefficient

-0.94

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Marker Therapeutics income statement and represents the costs associated with goods and services Marker Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Ebitda

Most indicators from Marker Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Marker Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.As of 12/13/2024, Enterprise Value is likely to grow to about 27.1 M, while Selling General Administrative is likely to drop slightly above 5.6 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	3.2M	3.7M	4.2M	2.3M
Interest Income	5.7K	248.1K	447.2K	291.5K

Reconciled Depreciation Interest Income

Marker Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Property Plant Equipment
Total Assets		0.49	-0.04	0.07	0.93	0.48	-0.81	-0.72	0.69	0.92	0.65	0.92	0.19	-0.05	0.54	0.55	-0.45	0.67	0.75	0.36	0.5	0.95	-0.13	0.06	-0.18	0.34
Short Long Term Debt Total	0.49		-0.03	0.14	0.34	0.97	-0.06	-0.74	0.68	0.21	0.76	0.21	0.59	0.19	0.81	0.7	-0.27	0.88	0.73	0.49	0.97	0.27	0.28	0.04	-0.72	0.82
Other Current Liab	-0.04	-0.03		0.94	-0.34	-0.01	0.07	0.02	0.07	-0.06	0.04	-0.06	-0.02	0.23	-0.06	0.03	-0.18	-0.02	-0.06	0.76	-0.01	-0.06	-0.13	0.24	0.06	-0.01
Total Current Liabilities	0.07	0.14	0.94		-0.27	0.1	0.08	-0.04	0.31	-0.02	0.23	-0.02	0.01	0.44	0.01	0.28	-0.22	0.13	0.0	0.89	0.11	-0.01	0.15	0.47	0.06	0.07
Total Stockholder Equity	0.93	0.34	-0.34	-0.27		0.34	-0.88	-0.66	0.49	0.94	0.44	0.94	0.12	-0.19	0.47	0.34	-0.36	0.54	0.71	0.0	0.36	0.95	-0.21	-0.1	-0.13	0.26
Property Plant And Equipment Net	0.48	0.97	-0.01	0.1	0.34		-0.1	-0.83	0.56	0.22	0.69	0.22	0.68	0.02	0.91	0.55	-0.29	0.91	0.81	0.42	1.0	0.27	0.08	-0.18	-0.78	0.91
Net Debt	-0.81	-0.06	0.07	0.08	-0.88	-0.1		0.54	-0.32	-0.97	-0.09	-0.97	0.11	0.12	-0.31	0.0	0.38	-0.3	-0.59	0.02	-0.12	-0.95	0.29	0.03	-0.1	-0.1
Retained Earnings	-0.72	-0.74	0.02	-0.04	-0.66	-0.83	0.54		-0.44	-0.59	-0.55	-0.59	-0.65	0.07	-0.94	-0.35	0.56	-0.86	-1.0	-0.29	-0.83	-0.64	0.16	0.28	0.67	-0.81
Accounts Payable	0.69	0.68	0.07	0.31	0.49	0.56	-0.32	-0.44		0.49	0.76	0.49	-0.02	0.21	0.39	0.82	-0.25	0.67	0.45	0.62	0.6	0.52	0.3	0.43	-0.06	0.37
Cash	0.92	0.21	-0.06	-0.02	0.94	0.22	-0.97	-0.59	0.49		0.31	1.0	-0.04	-0.07	0.36	0.24	-0.41	0.43	0.64	0.14	0.24	1.0	-0.21	0.06	0.03	0.15
Non Current Assets Total	0.65	0.76	0.04	0.23	0.44	0.69	-0.09	-0.55	0.76	0.31		0.31	0.47	0.02	0.52	0.93	-0.27	0.77	0.53	0.65	0.71	0.37	0.1	0.09	-0.45	0.46
Cash And Short Term Investments	0.92	0.21	-0.06	-0.02	0.94	0.22	-0.97	-0.59	0.49	1.0	0.31		-0.04	-0.07	0.36	0.24	-0.41	0.43	0.64	0.14	0.24	1.0	-0.21	0.06	0.03	0.15
Net Receivables	0.19	0.59	-0.02	0.01	0.12	0.68	0.11	-0.65	-0.02	-0.04	0.47	-0.04		0.02	0.71	0.29	-0.27	0.56	0.62	0.21	0.65	0.02	-0.04	-0.39	-0.87	0.69
Common Stock Total Equity	-0.05	0.19	0.23	0.44	-0.19	0.02	0.12	0.07	0.21	-0.07	0.02	-0.07	0.02		-0.03	0.28	-0.03	0.01	-0.09	0.35	0.02	-0.06	0.87	0.85	-0.02	0.02
Common Stock Shares Outstanding	0.54	0.81	-0.06	0.01	0.47	0.91	-0.31	-0.94	0.39	0.36	0.52	0.36	0.71	-0.03		0.31	-0.37	0.91	0.93	0.26	0.91	0.41	-0.03	-0.3	-0.7	0.95
Non Current Liabilities Total	0.55	0.7	0.03	0.28	0.34	0.55	0.0	-0.35	0.82	0.24	0.93	0.24	0.29	0.28	0.31		-0.21	0.6	0.34	0.66	0.58	0.29	0.38	0.4	-0.32	0.28
Inventory	-0.45	-0.27	-0.18	-0.22	-0.36	-0.29	0.38	0.56	-0.25	-0.41	-0.27	-0.41	-0.27	-0.03	-0.37	-0.21		-0.35	-0.55	-0.3	-0.29	-0.43	0.11	0.01	0.23	-0.25
Other Current Assets	0.67	0.88	-0.02	0.13	0.54	0.91	-0.3	-0.86	0.67	0.43	0.77	0.43	0.56	0.01	0.91	0.6	-0.35		0.85	0.47	0.92	0.48	0.05	-0.09	-0.56	0.85
Other Stockholder Equity	0.75	0.73	-0.06	0.0	0.71	0.81	-0.59	-1.0	0.45	0.64	0.53	0.64	0.62	-0.09	0.93	0.34	-0.55	0.85		0.25	0.81	0.68	-0.16	-0.28	-0.64	0.79
Total Liab	0.36	0.49	0.76	0.89	0.0	0.42	0.02	-0.29	0.62	0.14	0.65	0.14	0.21	0.35	0.26	0.66	-0.3	0.47	0.25		0.44	0.17	0.17	0.42	-0.18	0.28
Property Plant And Equipment Gross	0.5	0.97	-0.01	0.11	0.36	1.0	-0.12	-0.83	0.6	0.24	0.71	0.24	0.65	0.02	0.91	0.58	-0.29	0.92	0.81	0.44		0.29	0.09	-0.16	-0.74	0.91
Total Current Assets	0.95	0.27	-0.06	-0.01	0.95	0.27	-0.95	-0.64	0.52	1.0	0.37	1.0	0.02	-0.06	0.41	0.29	-0.43	0.48	0.68	0.17	0.29		-0.2	0.05	-0.02	0.2
Short Term Debt	-0.13	0.28	-0.13	0.15	-0.21	0.08	0.29	0.16	0.3	-0.21	0.1	-0.21	-0.04	0.87	-0.03	0.38	0.11	0.05	-0.16	0.17	0.09	-0.2		0.8	0.02	0.06
Common Stock	0.06	0.04	0.24	0.47	-0.1	-0.18	0.03	0.28	0.43	0.06	0.09	0.06	-0.39	0.85	-0.3	0.4	0.01	-0.09	-0.28	0.42	-0.16	0.05	0.8		0.36	-0.27
Non Currrent Assets Other	-0.18	-0.72	0.06	0.06	-0.13	-0.78	-0.1	0.67	-0.06	0.03	-0.45	0.03	-0.87	-0.02	-0.7	-0.32	0.23	-0.56	-0.64	-0.18	-0.74	-0.02	0.02	0.36		-0.66
Property Plant Equipment	0.34	0.82	-0.01	0.07	0.26	0.91	-0.1	-0.81	0.37	0.15	0.46	0.15	0.69	0.02	0.95	0.28	-0.25	0.85	0.79	0.28	0.91	0.2	0.06	-0.27	-0.66

Click cells to compare fundamentals

Marker Therapeutics Account Relationship Matchups

Marker Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	46.4M	45.6M	68.1M	34.4M	17.1M	13.6M
Other Current Liab	30.7K	2.7M	5.4M	3.6M	1.9M	2.5M
Total Current Liabilities	2.0M	6.4M	12.9M	7.8M	3.1M	4.6M
Total Stockholder Equity	44.1M	27.3M	44.0M	19.6M	14.1M	7.1M
Property Plant And Equipment Net	873.2K	21.2M	22.2M	17.8M	20.5M	21.5M
Net Debt	(43.4M)	(9.1M)	(30.5M)	(4.2M)	(15.1M)	(14.4M)
Retained Earnings	(327.5M)	(356.2M)	(398.1M)	(428.0M)	(436.3M)	(414.5M)
Accounts Payable	993K	2.9M	5.1M	1.1M	961K	1.3M
Cash	43.9M	21.4M	42.4M	11.8M	15.1M	9.6M
Cash And Short Term Investments	43.9M	21.4M	42.4M	11.8M	15.1M	9.6M
Net Receivables	56.2K	1.0M	237.0	2.4M	1.0M	1.1M
Common Stock Total Equity	10.6K	45.4K	45.7K	50.7K	58.3K	41.4K
Common Stock Shares Outstanding	4.6M	4.7M	7.7M	8.4M	8.8M	9.2M
Liabilities And Stockholders Equity	46.4M	45.6M	68.1M	34.4M	17.1M	13.6M
Non Current Liabilities Total	1.6M	280.2K	11.9M	11.2M	7.0M	0.0
Other Current Assets	1.5M	2.1M	3.6M	2.4M	2.0M	2.1M
Other Stockholder Equity	371.6M	383.5M	442.0M	447.6M	450.3M	472.8M
Total Liab	2.3M	18.3M	24.1M	14.8M	3.1M	6.0M
Property Plant And Equipment Gross	873.2K	21.2M	24.9M	17.8M	20.5M	21.5M
Total Current Assets	45.5M	24.4M	46.0M	16.6M	17.1M	10.3M
Short Term Debt	204.1K	777.6K	1.2M	577.2K	663.8K	714.4K
Common Stock	45.7K	50.7K	83.1K	8.4K	8.9K	8.4K
Non Currrent Assets Other	(472.0)	(21.2M)	2.2M	(17.8M)	(16.0M)	(15.2M)
Net Tangible Assets	59.3M	44.1M	27.3M	44.0M	50.6M	53.1M
Capital Surpluse	161.1M	365.4M	371.6M	383.5M	441.1M	230.6M
Net Invested Capital	44.1M	27.3M	44.0M	19.6M	14.1M	24.2M
Net Working Capital	43.5M	18.0M	33.1M	8.8M	14.1M	20.6M
Capital Stock	45.7K	50.7K	83.1K	8.4K	8.9K	8.4K

Pair Trading with Marker Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Marker Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marker Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Marker Stock

0.56	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.51	SLS	Sellas Life Sciences	Pair Corr
0.32	ERNA	Eterna Therapeutics	Pair Corr
0.32	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.31	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

The ability to find closely correlated positions to Marker Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marker Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marker Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marker Therapeutics to buy it.

The correlation of Marker Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marker Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marker Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Marker Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Marker Stock Analysis

When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC